Edition:
United States

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

1.62USD
11:25am EST
Change (% chg)

$0.01 (+0.94%)
Prev Close
$1.60
Open
$1.80
Day's High
$1.85
Day's Low
$1.58
Volume
96,672
Avg. Vol
66,215
52-wk High
$16.96
52-wk Low
$1.21

Latest Key Developments (Source: Significant Developments)

Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock
Monday, 13 Nov 2017 05:28pm EST 

Nov 13 (Reuters) - Anthera Pharmaceuticals Inc ::Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ .  Full Article

ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Anthera Pharmaceuticals Inc ::ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.58.‍ENDED Q3 OF 2017 WITH CASH AND CASH EQUIVALENTS TOTALING $6.1 MILLION, COMPARED TO $20.8 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Anthera Pharmaceuticals announces pricing of $15 mln private placement offering
Tuesday, 24 Oct 2017 08:30am EDT 

Oct 24 (Reuters) - Anthera Pharmaceuticals Inc :Anthera Pharmaceuticals announces pricing of $15 million private placement offering.Anthera Pharma - ‍To use net proceeds from offering for clinical research, development purposes for Sollpura, including result, simplicity, easy trials​.Anthera Pharmaceuticals Inc - ‍Investors have agreed to purchase 2.31 million shares of common stock at $1.25 per share​.  Full Article

Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network
Monday, 14 Aug 2017 08:30am EDT 

Aug 14 (Reuters) - Anthera Pharmaceuticals Inc :Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network.Says ‍topline data are expected at end of 2017 to early 2018, depending on speed of patient enrollment​.  Full Article

FDA grants orphan status to Anthera's kidney disease drug
Wednesday, 9 Aug 2017 04:00pm EDT 

Aug 10 (Reuters) - Anthera Pharmaceuticals Inc -:Anthera announces FDA orphan drug designation for blisibimod for the treatment of iga nephropathy.Anthera Pharmaceuticals Inc- ‍anthera anticipates reporting top-line data later this month for blisibimod​.  Full Article

Anthera Pharmaceuticals reports Q2 earnings per share $0.03
Wednesday, 9 Aug 2017 08:30am EDT 

Aug 9 (Reuters) - Anthera Pharmaceuticals Inc :Anthera Pharmaceuticals provides business update and reports 2017 second quarter financial results.Q2 earnings per share $0.03.Anthera Pharmaceuticals Inc - ‍bright, phase 2 study of blisibimod in iga nephropathy remains on track to report topline data in Q3​.Anthera Pharmaceuticals Inc - ‍ended Q2 of 2017 with cash and cash equivalents totaling $11.2 million, compared to $20.8 million as of December 31, 2016​.  Full Article

Anthera Pharmaceuticals announces results of Phase 3 clinical study of Sollpura
Monday, 10 Jul 2017 08:30am EDT 

July 10 (Reuters) - Anthera Pharmaceuticals Inc :Anthera Pharmaceuticals announces result Phase 3 clinical study of Sollpura will be included in the cystic fibrosis foundation therapeutics development network.Anthera Pharmaceuticals Inc - ‍topline data are expected at end of 2017 or early 2018, depending on speed of patient enrollment.​.Anthera - ‍CFF TDN approval may result in additional tdn investigational sites participating in study which could further accelerate patient recruitment in U.S.​.Says ‍result Phase 3 clinical study of Sollpura approved by CFF TDN protocol review committee​.  Full Article

Anthera pharmaceuticals reports qtrly loss per share $2.03
Wednesday, 10 May 2017 04:02pm EDT 

May 10 (Reuters) - Anthera Pharmaceuticals Inc :Anthera Pharmaceuticals provides business update and reports 2017 first quarter financial results.Qtrly loss per share $2.03.  Full Article

Anthera Pharmaceuticals announces 1-for-8 reverse split of stock
Friday, 28 Apr 2017 04:00pm EDT 

April 28 (Reuters) - Anthera Pharmaceuticals Inc ::Anthera Pharmaceuticals says announced reverse stock split of its common stock, effective as of April 28, 2017 at 5:00 P.M. Eastern Time .Anthera Pharmaceuticals announces 1-for-8 reverse split of stock.Reverse stock split will reduce number of shares of common stock issued and outstanding from about 80.6 million to about 10.1 million.  Full Article

Anson Funds Management reports 6.2 pct passive stake in Anthera Pharma as of March 15
Monday, 20 Mar 2017 04:04pm EDT 

Anthera Pharmaceuticals Inc :Anson funds management lp reports 6.2 percent passive stake in anthera pharmaceuticals inc as of march 15 - sec filing.  Full Article

BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura

* ANTHERA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA